Sanofi Total Non-Operating Income/Expense 2010-2025 | SNY

Sanofi total non-operating income/expense for the twelve months ending March 31, 2025 was $-1.071B, a 43.13% decline year-over-year.

  • Sanofi annual total non-operating income/expense for 2024 was $-0.972B, a 47.53% decline from 2023.
  • Sanofi annual total non-operating income/expense for 2023 was $-1.852B, a 811.58% decline from 2022.
  • Sanofi annual total non-operating income/expense for 2022 was $0.26B, a 141.98% decline from 2021.

Sanofi Total Non-Operating Income/Expense 2010-2025 | SNY

  • Sanofi annual total non-operating income/expense for 2024 was $-0.972B, a 47.53% decline from 2023.
  • Sanofi annual total non-operating income/expense for 2023 was $-1.852B, a 811.58% decline from 2022.
  • Sanofi annual total non-operating income/expense for 2022 was $0.26B, a 141.98% decline from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$796.4B
Johnson & Johnson (JNJ)$379.5B
AbbVie (ABBV)$306B
Novo Nordisk (NVO)$260.6B
Roche Holding AG (RHHBY)$248.1B
Novartis AG (NVS)$234.2B
Merck (MRK)$196.7B
Pfizer (PFE)$125.6B
Bayer (BAYRY)$23.7B
Innoviva (INVA)$1.1B